Adam B Weiner

List of Publications by Citations

53 papers	830 citations	14 h-index	28 g-index
62 ext. papers	1,143 ext. citations	5.5 avg, IF	4.28 L-index

#	Paper	IF	Citations
53	Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. *Science*, **2015**, 347, 842-7	33.3	317
52	National trends in the management of low and intermediate risk prostate cancer in the United States. *Journal of Urology*, **2015**, 193, 95-102	2.5	67
51	Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors. *Journal of Urology*, **2016**, 195, 290-6	2.5	42
50	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 6721-6730	12.9	35
49	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. *European Urology*, **2021**, 79, 374-383	10.2	28
48	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. *Nature Communications*, **2021**, 12, 935	17.4	25
47	Inflammatory Bowel Disease and the Risk of Prostate Cancer. *European Urology*, **2019**, 75, 846-852	10.2	24
46	Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 164.e11-7	2.8	22
45	Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013). *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 237.e9-237.e17	2.8	22
44	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. *Urology*, **2015**, 86, 777-82	1.6	22
43	Intravesical therapy for bladder cancer. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 889-901	4	21
42	The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013). *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 91.e1-91.e6	2.8	18
41	Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. *Cancer*, **2017**, 123, 245-252	6.4	15
40	National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. *Journal of Urology*, **2016**, 195, 1383-1389	2.5	13
39	Risk of lymph node metastases in pathological gleason scored prostate adenocarcinoma: Analysis of institutional and population-based databases. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 31.e1-31.e6	2.8	12
38	Prostate Cancer: A Contemporary Approach to Treatment and Outcomes. *Medical Clinics of North America*, **2018**, 102, 215-229	7	11
37	Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. *Journal of Urology*, **2015**, 193, 826-31	2.5	10

36	Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. *International Journal of Cancer*, **2020**, 147, 2735-2742	7.5	9
35	Quality of Life-Focused Decision-Making for Prostate Cancer. *Current Urology Reports*, **2019**, 20, 57	2.9	8
34	Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 70.e1-7	2.8	8
33	Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. *Current Treatment Options in Oncology*, **2019**, 20, 69	5.4	8
32	A PRC2-independent function for EZH2 in regulating rRNA 2SO methylation and IRES-dependent translation. *Nature Cell Biology*, **2021**, 23, 341-354	23.4	8
31	Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. *European Urology Oncology*, **2019**, 2, 304-310	6.7	8
30	Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. *Cancer*, **2020**, 126, 3229-3236	6.4	7
29	The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. *Urology Practice*, **2020**, 7, 145-151	0.8	6
28	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. *European Urology Oncology*, **2020**, 4, 955-955	6.7	5
27	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
26	Rates and Predictors of Conversion to Open Surgery During Minimally Invasive Radical Cystectomy. *Journal of Endourology*, **2018**, 32, 488-494	2.7	4
25	Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. *Journal of Urology*, **2020**, 203, 933-939	2.5	4
24	Insurance coverage, stage at diagnosis, and time to treatment following dependent coverage and Medicaid expansion for men with testicular cancer. *PLoS ONE*, **2020**, 15, e0238813	3.7	4
23	Contemporary Comparison of Open to Robotic Prostatectomy at a Veteran's Affairs Hospital. *Military Medicine*, **2019**, 184, e330-e337	1.3	4
22	It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?. *Cancer*, **2021**, 127, 3354-3360	6.4	3
21	Radiographic hemithorax white-out following percutaneous nephrolithotomy. *Urology Case Reports*, **2018**, 17, 1-3	0.5	2
20	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 353.e1-353.e8	2.8	2
19	Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 261-267	6.2	2

18	Predictors of use and overall survival for patients undergoing metastasectomy for bladder cancer in a national cohort. *International Journal of Urology*, **2020**, 27, 736-741	2.3	1
17	Medicaid Expansion Did not Improve Time to Treatment for Young Patients With Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2020**, 18, e386-e390	3.3	1
16	Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis. *Cancer*, **2021**, 127, 2895-2904	6.4	1
15	The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. *Journal of Urology*, **2018**, 200, 1048-1055	2.5	1
14	Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. *Clinical Genitourinary Cancer*, **2021**, 19, 388-395	3.3	1
13	Bladder Cancer Following Medicaid Expansion: No Changes in the Diagnosis of Muscle-Invasive Disease and Time to Treatment. *Bladder Cancer*, **2020**, 6, 143-150	1	0
12	Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. *Bladder Cancer*, **2021**, 7, 23-31	1	0
11	Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment. *Bladder Cancer*, **2021**, 7, 347-354	1	0
10	Robotic-Assisted vs Laparoscopic Radical Nephrectomy. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1165	27.4	
9	Radical Cystectomy with Ileal Conduit Urinary Diversion in a Patient with a Left Ventricular Assist Device. *Case Reports in Urology*, **2015**, 2015, 484679	0.5	
8	Willingness to Participate in Home Screening for Urologic Cancers in the General Population: An Online Survey of Over 1400 Adults. *Urology*, **2020**, 136, 35-40	1.6	
7	Editorial Comment. *Journal of Urology*, **2021**, 205, 1284-1285	2.5	
6	n = 1. *Academic Medicine*, **2018**, 93, 1820	3.9	
5	Editorial Comment. *Journal of Urology*, **2018**, 200, 994-995	2.5	
4	Insurance coverage, stage at diagnosis, and time to treatment following dependent coverage and Medicaid expansion for men with testicular cancer **2020**, 15, e0238813		
3	Insurance coverage, stage at diagnosis, and time to treatment following dependent coverage and Medicaid expansion for men with testicular cancer **2020**, 15, e0238813		
2	Insurance coverage, stage at diagnosis, and time to treatment following dependent coverage and Medicaid expansion for men with testicular cancer **2020**, 15, e0238813		
1	Insurance coverage, stage at diagnosis, and time to treatment following dependent coverage and Medicaid expansion for men with testicular cancer **2020**, 15, e0238813		